Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
17
12
2021
received:
03
05
2021
accepted:
17
12
2021
pubmed:
15
1
2022
medline:
16
11
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with a dismal prognosis. We investigated if lipid metabolism is disrupted in CCA and its role in tumor proliferation. The in vitro and in vivo tumorigenic capacity of five human CCA cell lines was analyzed. Proteome, lipid content, and metabolic fluxes were evaluated in CCA cells and compared with normal human cholangiocytes (NHC). The Akt1/NOTCH1 intracellular cytoplasmic domain (Nicd1)-driven CCA mouse model was also evaluated. The proteome of CCA cells was enriched in pathways involved in lipid and lipoprotein metabolism. The EGI1 CCA cell line presented the highest tumorigenic capacity. Metabolic studies in high (EGI1) versus low (HUCCT1) proliferative CCA cells in vitro showed that both EGI1 and HUCCT1 incorporated more fatty acids (FA) than NHC, leading to increased triglyceride storage, also observed in Akt1/Nicd1-driven CCA mouse model. The highly proliferative EGI1 CCA cells showed greater uptake of very-low-density and HDLs than NHC and HUCCT1 CCA cells and increased cholesteryl ester content. The FA oxidation (FAO) and related proteome enrichment were specifically up-regulated in EGI1, and consequently, pharmacological blockade of FAO induced more pronounced inhibition of their tumorigenic capacity compared with HUCCT1. The expression of acyl-CoA dehydrogenase ACADM, the first enzyme involved in FAO, was increased in human CCA tissues and correlated with the proliferation marker PCNA. Highly proliferative human CCA cells rely on lipid and lipoprotein uptake to fuel FA catabolism, suggesting that inhibition of FAO and/or lipid uptake could represent a therapeutic strategy for this CCA subclass.
Sections du résumé
BACKGROUND AND AIMS
Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with a dismal prognosis. We investigated if lipid metabolism is disrupted in CCA and its role in tumor proliferation.
APPROACH AND RESULTS
The in vitro and in vivo tumorigenic capacity of five human CCA cell lines was analyzed. Proteome, lipid content, and metabolic fluxes were evaluated in CCA cells and compared with normal human cholangiocytes (NHC). The Akt1/NOTCH1 intracellular cytoplasmic domain (Nicd1)-driven CCA mouse model was also evaluated. The proteome of CCA cells was enriched in pathways involved in lipid and lipoprotein metabolism. The EGI1 CCA cell line presented the highest tumorigenic capacity. Metabolic studies in high (EGI1) versus low (HUCCT1) proliferative CCA cells in vitro showed that both EGI1 and HUCCT1 incorporated more fatty acids (FA) than NHC, leading to increased triglyceride storage, also observed in Akt1/Nicd1-driven CCA mouse model. The highly proliferative EGI1 CCA cells showed greater uptake of very-low-density and HDLs than NHC and HUCCT1 CCA cells and increased cholesteryl ester content. The FA oxidation (FAO) and related proteome enrichment were specifically up-regulated in EGI1, and consequently, pharmacological blockade of FAO induced more pronounced inhibition of their tumorigenic capacity compared with HUCCT1. The expression of acyl-CoA dehydrogenase ACADM, the first enzyme involved in FAO, was increased in human CCA tissues and correlated with the proliferation marker PCNA.
CONCLUSIONS
Highly proliferative human CCA cells rely on lipid and lipoprotein uptake to fuel FA catabolism, suggesting that inhibition of FAO and/or lipid uptake could represent a therapeutic strategy for this CCA subclass.
Identifiants
pubmed: 35030285
doi: 10.1002/hep.32344
pmc: PMC9790564
pii: 01515467-202212000-00008
doi:
Substances chimiques
Proteome
0
Lipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1617-1633Informations de copyright
© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS‐CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–80.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.
Nakanuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol. 2015;29(2):277–93.
Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci. 2015;22(2):94–100.
Clements O, Eliahoo J, Kim JU, Taylor‐Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta‐analysis. J Hepatol. 2020;72(1):95–103.
Cardinale V, Renzi A, Carpino G, Torrice A, Bragazzi MC, Giuliante F, et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am J Pathol. 2015;185(6):1724–39.
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829–40.
Montal R, Sia D, Montironi C, Leow WQ, Esteban‐Fabró R, Pinyol R, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73(2):315–27.
Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–61.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.
Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748–66.
Pastore M, Lori G, Gentilini A, Taddei ML, Di Maira G, Campani C, et al. Multifaceted aspects of metabolic plasticity in human cholangiocarcinoma: an overview of current perspectives. Cells. 2020;9(3):596.
Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122(8):2911–5.
Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT‐mTORC1‐RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140(3):1071–83.
Li L, Che L, Tharp KM, Park H‐M, Pilo MG, Cao D, et al. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016;63(6):1900–13.
Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021–31.
Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole‐genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–35.
Banales JM, Sáez E, Úriz M, Sarvide S, Urribarri AD, Splinter P, et al. Up‐regulation of microRNA 506 leads to decreased Cl−/HCO3− anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56(2):687–97.
Urribarri AD, Munoz‐Garrido P, Perugorria MJ, Erice O, Merino‐Azpitarte M, Arbelaiz A, et al. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut. 2014;63(10):1658–67.
Merino‐Azpitarte M, Lozano E, Perugorria MJ, Esparza‐Baquer A, Erice O, Santos‐Laso Á, et al. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J Hepatol. 2017;67(1):72–83.
Buqué X, Cano A, Miquilena‐Colina ME, García‐Monzón C, Ochoa B, Aspichueta P. High insulin levels are required for FAT/CD36 plasma membrane translocation and enhanced fatty acid uptake in obese Zucker rat hepatocytes. Am J Physiol Endocrinol Metab. 2012;303(4):E504–14.
Aspichueta P, Pérez S, Ochoa B, Fresnedo O. Endotoxin promotes preferential periportal upregulation of VLDL secretion in the rat liver. J Lipid Res. 2005;46(5):1017–26.
Huynh FK, Green MF, Koves TR, Hirschey MD. Measurement of fatty acid oxidation rates in animal tissues and cell lines. Methods Enzymol. 2014;542:391–405.
González‐Romero F, Mestre D, Aurrekoetxea I, O'Rourke CJ, Andersen JB, Woodhoo A, et al. E2F1 and E2F2‐mediated repression of CPT2 establishes a lipid‐rich tumor‐promoting environment. Cancer Res. 2021;81(11):2874–87.
Nakagawa R, Hiep NC, Ouchi H, Sato Y, Harada K. Expression of fatty‐acid‐binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location. Med Mol Morphol. 2020;53(1):42–9.
Scherer D, Dávila López M, Goeppert B, Abrahamsson S, González Silos R, Nova I, et al. RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling. Cancers (Basel). 2020;12(9):2510.
Shiomi M, Koike T, Ishi T. Genetically modified animal models for lipoprotein research. In: Frank S, Kostner G, ed. Lipoproteins ‐ Role in Health and Diseases . IntechOpen; 2012:533–60.
Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221–32.
Martínez‐Uña M, Varela‐Rey M, Cano A, Fernández‐Ares L, Beraza N, Aurrekoetxea I, et al. Excess S‐adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology. 2013;58(4):1296–305.
van der Veen JN, Lingrell S, Vance DE. The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver. J Biol Chem. 2012;287(28):23418–26.
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue‐based map of the human proteome. Science. 2015;347(6220):1260419.
Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2‐deoxyglucose and etomoxir. Int J Cancer. 2008;123(2):476–83.
Chen T, Wu G, Hu H, Wu C. Enhanced fatty acid oxidation mediated by CPT1C promotes gastric cancer progression. J Gastrointest Oncol. 2020;11(4):695–707.
Xu AN, Wang B, Fu J, Qin W, Yu T, Yang Z, et al. Diet‐induced hepatic steatosis activates Ras to promote hepatocarcinogenesis via CPT1α. Cancer Lett. 2019;442:40–52.
Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, et al. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol. 2021;74(6):1373–85.
Maan M, Peters JM, Dutta M, Patterson AD. Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun. 2018;504(3):582–9.
Kreuzaler P, Panina Y, Segal J, Yuneva M. Adapt and conquer: metabolic flexibility in cancer growth, invasion and evasion. Mol Metab. 2020;33:83–101.
Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245–93.
Buranrat B, Senggunprai L, Prawan A, Kukongviriyapan V. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells. Life Sci. 2016;153:41–9.
Liu Z, Alsaggaf R, McGlynn KA, Anderson LA, Tsai H‐T, Zhu B, et al. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut. 2019;68(8):1458–64.
Halama A, Kulinski M, Dib SS, Zaghlool SB, Siveen KS, Iskandarani A, et al. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. Cancer Lett. 2018;430:133–47.
Zuurbier CJ, Bertrand L, Beauloye CR, Andreadou I, Ruiz‐Meana M, Jespersen NR, et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction. J Cell Mol Med. 2020;24(11):5937–54.
Yizhak K, Gaude E, Le Dévédec S, Waldman YY, Stein GY, van de Water B, et al. Phenotype‐based cell‐specific metabolic modeling reveals metabolic liabilities of cancer. eLife. 2014;3:e03641.
Lupien LE, Bloch K, Dehairs J, Traphagen NA, Feng WW, Davis WL, et al. Endocytosis of very low‐density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells. J Lipid Res. 2020;61(2):205–18.
Lo PK, Yao Y, Zhou Q. Inhibition of LIPG phospholipase activity suppresses tumor formation of human basal‐like triple‐negative breast cancer. Sci Rep. 2020;10(1):8911.
Seo J, Jeong DW, Park JW, Lee KW, Fukuda J, Chun YS. Fatty‐acid‐induced FABP5/HIF‐1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun Biol. 2020;3(1):638.
Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006;3(5):321–31.
Urman JM, Herranz JM, Uriarte I, Rullán M, Oyón D, González B, et al. Pilot multi‐omic analysis of human bile from benign and malignant biliary strictures: a machine‐learning approach. Cancers. 2020;12(6):1644.
Wu T. Cyclooxygenase‐2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 2005;1755(2):135–50.